The European Medicine's Agency's Committee for Medicinal Products for Human Use (CHMP) approved enzalutamide in this indication on 25 March 2021.
Following receipt of positive CHMP opinion a closed part 2 committee
meeting took place on 8th April 2021.
The Appraisal Committee has prepared a Final Appraisal Document (FAD) on enzalutamide for treating hormone-sensitive metastatic prostate.
The FAD was published on the NICE website on Tuesday 8 June 2021.